PharmaResources (Shanghai) Co., Ltd.

SZSE:301230 Lagerbericht

Marktkapitalisierung: CN¥3.4b

PharmaResources (Shanghai) Vergangene Ertragsentwicklung

Vergangenheit Kriterienprüfungen 0/6

PharmaResources (Shanghai)'s earnings have been declining at an average annual rate of -11.6%, while the Life Sciences industry saw earnings growing at 17.2% annually. Revenues have been growing at an average rate of 12.6% per year. PharmaResources (Shanghai)'s return on equity is 0.7%, and it has net margins of 1.3%.

Wichtige Informationen

-11.6%

Wachstumsrate der Gewinne

-18.0%

EPS-Wachstumsrate

Life Sciences Wachstum der Industrie26.8%
Wachstumsrate der Einnahmen12.6%
Eigenkapitalrendite0.7%
Netto-Marge1.3%
Letzte Ertragsaktualisierung30 Sep 2024

Jüngste Aktualisierungen vergangener Leistungen

PharmaResources (Shanghai) (SZSE:301230) Posted Weak Earnings But There Is More To Worry About

May 02
PharmaResources (Shanghai) (SZSE:301230) Posted Weak Earnings But There Is More To Worry About

Recent updates

PharmaResources (Shanghai) Co., Ltd.'s (SZSE:301230) P/S Is Still On The Mark Following 39% Share Price Bounce

Oct 10
PharmaResources (Shanghai) Co., Ltd.'s (SZSE:301230) P/S Is Still On The Mark Following 39% Share Price Bounce

PharmaResources (Shanghai) (SZSE:301230) Posted Weak Earnings But There Is More To Worry About

May 02
PharmaResources (Shanghai) (SZSE:301230) Posted Weak Earnings But There Is More To Worry About

Aufschlüsselung der Einnahmen und Ausgaben

Wie PharmaResources (Shanghai) Geld verdient und ausgibt. Basierend auf den neuesten gemeldeten Einnahmen der letzten zwölf Monate.


Gewinn- und Umsatzhistorie

SZSE:301230 Einnahmen, Ausgaben und Erträge (CNY Millions)
DatumEinnahmenUmsatzAllgemeine und VerwaltungskostenF&E-Ausgaben
30 Sep 2451478145
30 Jun 24518218041
31 Mar 24499267838
31 Dec 23490387437
30 Sep 23514757139
30 Jun 23511807038
31 Mar 23496728035
01 Jan 23479678033
30 Sep 22485727930
30 Jun 22465727726
31 Mar 22458736422
01 Jan 22448746417
30 Sep 21377486112
31 Dec 20283494312
31 Dec 19245473710
30 Jun 19171303510
31 Mar 1914919359
31 Dec 181268358
30 Sep 18127102715
30 Jun 18127112516
31 Mar 18131163013
31 Dec 17135203410
30 Sep 1713120385
30 Jun 1712719410
31 Mar 1711716400
31 Dec 1610714380
30 Sep 169511360
30 Jun 16849350
31 Mar 16807340
01 Jan 16766320

Qualität der Erträge: 301230 has a high level of non-cash earnings.

Wachsende Gewinnspanne: 301230's current net profit margins (1.3%) are lower than last year (14.6%).


Analyse von freiem Cashflow und Gewinn


Analyse des Gewinnwachstums in der Vergangenheit

Ergebnisentwicklung: 301230's earnings have declined by 11.6% per year over the past 5 years.

Beschleunigtes Wachstum: 301230's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Erträge im Vergleich zur Industrie: 301230 had negative earnings growth (-90.8%) over the past year, making it difficult to compare to the Life Sciences industry average (-14.4%).


Eigenkapitalrendite

Hohe Eigenkapitalrendite: 301230's Return on Equity (0.7%) is considered low.


Kapitalrendite


Rendite auf das eingesetzte Kapital


Entdecken Sie starke Unternehmen, die in der Vergangenheit erfolgreich waren